A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: Xarelto

  • Coronavirus for patients: Plan your blood thinner medication refills

    Beth Waldron, MA writes….For patients on life-saving therapies like blood thinners (anticoagulants) having several weeks supply of medication on hand during the coronavirus outbreak is important not only to reduce the need to be out in public, but to ensure you have everything you need already at home if you do get sick. However, getting…

  • Antiphospholipid Syndrome: Can the New Oral Anticoagulants Be Used?

    Stephan Moll, MD and Damon Houghton, MD write … In patients with antiphospholipid syndrome (APS) who require anticoagulation for the treatment of DVT or PE, warfarin or a low molecular weight heparin have traditionally been used. A question that comes up is whether one of the new oral anticoagulants (DOACs) can be effectively and safely…

  • Heavier Menstrual Bleeding on Xarelto?

    Stephan Moll, MD writes… Interesting and noteworthy observations published in the last 2 weeks:  Heavy menstrual bleeding appears to occur more commonly with Xarelto® than with warfarin [ref 1] and may be also more common with Xarelto® than with Eliquis® [ref 2].

  • Antidotes for the New Oral Anticoagulants: Update

    Stephan Moll, MD writes (on Nov 7th, 2014)… A N Engl J Med publication this week [ref 1] reports on a new reversal agent (PER977 = Aripazine = ciraparantag) that may be effective against a number of different new oral anticoagulants.

  • Xarelto Dosing in Obese Patients

    Stephan Moll, MD writes…  Is there a dose change or limitation for the use of Xarelto® (rivaroxaban) in very obese or underweight patients?

  • Pradaxa (Dabigatran) FDA-Approved for DVT and PE

    Stephan Moll, MD writes…  Today the FDA approved Pradaxa (dabigatran) for the treatment of venous thromboembolism, based on the phase 3 RECOVER and RECOVER II trials.  The dose is 150 mg twice daily for patients with a GFR > 30 ml/min.  Due to the design of the RECOVER and RECOVER II trials, the drug is approved…

  • FDA to Review Eliquis (Apixaban) for DVT and PE Treatment

    Stephan Moll, MD writes… On Dec 19th the FDA accepted the application by Bristol-Myers Squibb (BMS) and Pfizer for review of Eliquis (apixaban) for the treatment of DVT and PE. The press release of BMS is here.  The goal date for a decision by the FDA is August 25, 2014.

  • New Oral Anticoagulants for DVT and PE: Update on FDA Applications

    Stephan Moll, MD writes…   1.  Pradaxa (Dabigatran) Today, August 28th, 2013, it was announced that the FDA is reviewing the application by Boehringer-Ingelheim to get Pradaxa (dabigatran) approved for use in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) – details here. At present, in the US, Pradaxa is only FDA-approved for…